| Karen A Sylvara, DO | |
|
502 S Baltimore St, Kirksville, MO 63501-3728 | |
| (660) 665-5570 | |
| (660) 665-2898 |
| Full Name | Karen A Sylvara |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Experience | 33 Years |
| Location | 502 S Baltimore St, Kirksville, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003812090 | NPI | - | NPPES |
| 243370202 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 101191 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Macon County Samaritan Memorial Hospital | Macon, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Macon County Samaritan Hospital | 1456261395 | 35 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Entity Name | John T Sylvara |
|---|---|
| Entity Type | Practitioner - Family Practice |
| Entity Identifiers | NPI Number: 1881662724 PECOS PAC ID: 4587623830 Enrollment ID: I20041012000904 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Entity Name | General John J Pershing Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982612461 PECOS PAC ID: 2860306750 Enrollment ID: O20031117000114 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Entity Name | Macon County Samaritan Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548215106 PECOS PAC ID: 1456261395 Enrollment ID: O20040121000179 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Entity Name | General John J Pershing Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487616256 PECOS PAC ID: 2860306750 Enrollment ID: O20050422000230 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Entity Name | Ripley Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720606023 PECOS PAC ID: 1254757446 Enrollment ID: O20200819000175 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen A Sylvara, DO 502 S Baltimore St, Kirksville, MO 63501-3728 Ph: (660) 665-5570 | Karen A Sylvara, DO 502 S Baltimore St, Kirksville, MO 63501-3728 Ph: (660) 665-5570 |
News Archive
Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types-the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles-that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.
"If left unaddressed, [non-communicable diseases (NCDs)] will lead to more death, disability and the implosion of already overburdened health systems in developing countries at huge cost to individuals, families, businesses and society," Peter Piot, director of the London School of Hygiene and Tropical Medicine and former UNAIDS executive director, writes in the Huffington Post "Impact" blog, adding, "Like AIDS, NCDs are a problem for rich and poor countries alike, but the poor suffer the most."
PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, announced that is has received $6 million USD in a Series A financing. OrbiMed's Caduceus Asia Partners and Novartis Korea Venture Fund co-led the round, with additional participation from an international syndicate including Green Cross, Tong Yang and Saehan Venture Fund.
Writing in KPLU's "Humanosphere" blog, Tom Paulson responds to last week's announcement of results from an ongoing clinical trial of an experimental malaria vaccine, saying, "Despite the hype and fanfare, many experts at the Seattle meeting said this experimental vaccine actually so far represents only incremental progress - a scientific achievement which may still turn out to have little practical utility in the real world."
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
› Verified 3 days ago
Dr. Katherine Lynne Holbrook, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 800 W Jefferson St, Kirksville, MO 63501 Phone: 660-626-2223 | |
Molly Christine Thompson, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 315 S Osteopathy Ave, Kirksville, MO 63501 Phone: 660-785-1000 | |
Dr. Stephanie Gonzales, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 315 S Osteopathy Ave, Kirksville, MO 63501 Phone: 660-785-1000 | |
Dr. James L Bowers, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1415 E Scott St, Kirksville, MO 63501 Phone: 660-665-1767 Fax: 660-665-1767 | |
Dr. Ronald Leland Phillips, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Crown Dr, Suite 200, Kirksville, MO 63501 Phone: 660-665-3838 Fax: 660-665-0130 | |
Dr. Steven R Lyons, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Jefferson St, Kirksville, MO 63501 Phone: 660-785-1000 |